Boston Scientific Target of Unusually High Options Trading (NYSE:BSX)

Key Points

• Surge in call buying: Traders purchased 60,185 call options on Tuesday, a 154% increase versus typical daily call volume, indicating unusually heavy bullish options activity.
• Shares near 52‑week low despite earnings beat: BSX traded to $59.46 on heavy volume (close to its 52‑week low of $59.39) even after a modest EPS beat and guidance of $0.780–0.800 for Q1 2026 and $3.430–3.490 for FY2026.
• Heightened risk and mixed analyst views: Multiple securities‑fraud class actions, notable insider selling by the CEO, and recent analyst price‑target cuts have increased headline and downside risk, though the consensus rating remains a "Moderate Buy" with an average target of $102.59.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) saw unusually large options trading activity on Tuesday. Stock traders bought 60,185 call options on the company. This represents an increase of 154% compared to the typical daily volume of 23,684 call options.

Boston Scientific Stock Performance

Boston Scientific stock traded down $1.53 during mid-day trading on Tuesday, reaching $59.46. The company had a trading volume of 26,722,353 shares, compared to its average volume of 15,771,313. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. Boston Scientific has a 52 week low of $59.39 and a 52 week high of $109.50. The company has a 50 day moving average of $69.34 and a 200-day moving average of $86.58. The firm has a market cap of $88.37 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 0.99 and a beta of 0.78.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period last year, the business earned $0.70 earnings per share. The firm's revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts expect that Boston Scientific will post 3.45 EPS for the current fiscal year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several analysts continue to rate BSX as a Buy and highlight meaningful upside from current levels, providing support under the shares despite recent weakness. Boston Scientific Stock Is Trending Today: What To Know Now
• Positive Sentiment: Some research firms reaffirm bullish ratings (e.g., Piper Sandler Overweight) and highlight product/clinical catalysts (WATCHMAN / CHAMPION‑AF trial data) that could expand indications and long‑term growth if commercial adoption follows. Here’s What Piper Sandler Thinks About Boston Scientific Corp (BSX) Now
• Neutral Sentiment: Q1 2026 earnings preview and guidance are front and center — the company reports imminently and investors are positioning ahead of the print. Expectations and guidance will be the immediate catalyst for a directional move. Boston Scientific Q1 2026 Earnings Preview
• Negative Sentiment: Multiple law firms have filed or solicited plaintiffs in securities‑fraud class actions covering the July 2025–Feb 2026 period, creating headline/legal risk and prompting lead‑plaintiff deadline notices that can pressure sentiment. Bronstein, Gewirtz & Grossman LLC Urges Boston Scientific Investors to Act
• Negative Sentiment: Analysts have trimmed price targets recently (Stifel, Truist among others); while ratings are largely maintained, the cuts and cautious previews are weighing on the stock and support the view that estimates are being re‑priced. Boston Scientific Plunges to 52-Week Low as Wall Street Adjusts Forecasts
• Negative Sentiment: Pre‑earnings risk‑off positioning, reported insider selling and large institutional reductions in recent filings increase downside pressure and volatility into the print. Investors appear to be de‑risking while awaiting clarity on revenue/procedure trends. Boston Scientific slips as investors stay cautious ahead of results

Wall Street Analysts Forecast Growth

Several research firms have commented on BSX. TD Cowen decreased their target price on shares of Boston Scientific from $115.00 to $100.00 and set a "buy" rating for the company in a research report on Monday, February 2nd. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research note on Monday, February 2nd. Jefferies Financial Group restated a "buy" rating on shares of Boston Scientific in a research note on Monday, March 16th. Truist Financial reduced their price objective on shares of Boston Scientific from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Wednesday, April 15th. Finally, Citigroup reduced their price objective on shares of Boston Scientific from $94.00 to $87.00 and set a "buy" rating for the company in a research note on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $102.59.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.34% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently made changes to their positions in the business. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC acquired a new stake in Boston Scientific during the 2nd quarter worth approximately $26,000. Main Street Financial Solutions LLC raised its holdings in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock valued at $812,000 after purchasing an additional 1,971 shares during the last quarter. Ieq Capital LLC grew its stake in shares of Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock valued at $13,275,000 after buying an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC grew its stake in shares of Boston Scientific by 56.2% in the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock valued at $763,000 after buying an additional 2,556 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.